Fortress Biotech Inc (FBIO) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

RahaBoss Nov. 14 at 8:31 PM

$FBIO 30,000 shares at $2.01 average locked and loaded....

0 · Reply

makrodimutross Nov. 14 at 6:36 PM

$FBIO $FBIOP It is also interesting to note that Oaktree has exercised half of their warrants.

0 · Reply

HedgeAlerts Nov. 14 at 5:52 PM

Hedge Alert Live - Protect Your Portfolio Contract: $FBIO $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.15 - $0.17 Exit Price Target: $0.41 Profit Margin: +140% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

HJAC Nov. 14 at 4:23 PM

$FBIO Does anyone realize that FBIO also includes MBIO? MBIO is pretty inexpensive currently. Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

1 · Reply

makrodimutross Nov. 14 at 4:03 PM

$FBIOP $FBIO Here's where they put Crystalys, and the expired liabilities from Urica. You can see from 2024 how much they've amortized all other intangible assets... this company is an absolute sleeper build.

1 · Reply

makrodimutross Nov. 14 at 3:52 PM

$FBIO $FBIOP close! But SG+A is actually better than i anticipated! 17.4m in Q3! Also like that they've brought the fair value of Crystalys into the financial statements... This is an overall excellent Q, and the pivot to a cashflow positive state is getting closer.

2 · Reply

Sawnchey Nov. 14 at 2:23 PM

$FBIO $FBIOP Nice to be able to review the financials without the legacy element of Checkpoint murkying the waters. Enclosed is (in my opinion) the most important part of the 10-Q. We can see that Journey is coming very close to profitability, Mustang and Avenue are not close to any kind of meaningful product commercialisation but cost almost nothing to keep going. The main Fortress operation is also relatively cheap to run and those Unloxcyt royalties will begin trickling in at some point in the next year and we will hopefully see additional income upon the eventual hopeful success of CUTX-101. In short the situation is very stable while we await the Emrosi growth and any further milestones that can tip the group into sustained profitability. As for the preferred dividend, it is still paused, but the outstanding balance of 10M is not so high that a meaningful milestone can't unlock it in the future. I am going to keep slowly accumulating shares when they look cheap and waiting.

1 · Reply

d_risk Nov. 14 at 1:50 PM

$FBIO - Fortress Biotech, Inc. - 10Q - Updated Risk Factors FBIO’s latest 10-Q risk factors spotlight heightened FDA and regulatory uncertainties, clinical trial and supply chain disruptions, expanded IP and cybersecurity threats, new debt and financing risks, and a wave of fresh concerns—from AI and disaster recovery to Nasdaq delisting, tax law changes, and market volatility—reflecting a broader, more detailed risk landscape for 2025. #Biotechnology #MarketVolatility #AIRisk #DebtFinancing #Cybersecurity #SupplyChain #ClinicalTrials #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/FBIO/10-Q/2025-11-14

0 · Reply

FinSUN Nov. 14 at 1:44 PM

$FBIO Again, the CRL made it miss earnings. It would have been a full beat

1 · Reply

FinSUN Nov. 14 at 1:42 PM

$FBIO beat EPS, lower on revenue. Mixed.

0 · Reply

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Nov 12, 2025, 10:41 PM EST - 1 day ago

Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript

FBIOP

Nov 12, 2025, 4:01 PM EST - 2 days ago

Market Cap	77.96M
Revenue (ttm)	57.68M
Net Income (ttm)	-46.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-79.75%
Debt to Equity Ratio	1.44

Volume	434,966
Avg Vol	1,082,512
Day's Range	N/A - N/A
Shares Out	29.76M
Stochastic %K	31%
Beta	1.60
Analysts	Sell
Price Target	$10.50